Healthcare Industry News:  Bradley Pharmaceuticals 

Biopharmaceuticals

 News Release - June 28, 2007

Bradley Pharmaceuticals Launches Kerol(TM) Topical Suspension and ROSULA(R) Clarifying Wash(TM)

FAIRFIELD, N.J., June 28 (HSMN NewsFeed) -- Bradley Pharmaceuticals, Inc. (NYSE: BDY ) today announced that its Doak Dermatologics subsidiary recently launched two new product line extensions from its Kerol(TM) and ROSULA® brand portfolios.

Kerol(TM) Topical Suspension (50% Urea), a potent keratolytic in a vehicle containing lactic acid & salicylic acid, is an addition to the line of Kerol(TM) Redi-Cloths keratolytic moisturizers. Kerol(TM) Topical Suspension is indicated for the treatment of hyperkeratotic conditions such as dry, rough skin, dermatitis, psoriasis, xerosis, ichthyosis, eczema, keratosis pilaris, keratosis palmaris, keratoderma, corns and calluses.

ROSULA® Clarifying Wash(TM) (sodium sulfacetamide 10% and sulfur 4%) is the fourth product launched under the ROSULA® brand. The new ROSULA® Clarifying Wash(TM) formulation combines 10% sodium sulfacetamide and 4% sulfur in a urea vehicle and is indicated for the treatment of acne vulgaris, acne rosacea and seborrrheic dermatitis. Bradley launched the ROSULA® brand in 2003 with ROSULA® Aqueous Gel which was followed by ROSULA® Aqueous Cleanser and ROSULA® NS Medicated Pads.

"Our Kerol(TM) and ROSULA® brands have been well received by physicians and patients and we anticipate that these new therapies will likewise be well received," stated Daniel Glassman, President and CEO of Bradley Pharmaceuticals. "One important part of our business strategy is to develop brands through life cycle management that add value to the medical community and patient care, and we believe that Kerol(TM) Topical Suspension and ROSULA® Clarifying Wash(TM) both will meet this objective."

Important Product Safety Information About Kerol(TM) Topical Suspension:

KEROL(TM) Topical Suspension is for external use only. Avoid contact with eyes, lips or mucous membranes. If redness or irritation occurs, discontinue use.

Important Product Safety Information About ROSULA® Clarifying Wash(TM):

ROSULA® Clarifying Wash(TM) is contraindicated in persons with known or suspected hypersensitivity to sulfonamides or sulfur. ROSULA® Clarifying Wash(TM) is not to be used by patients with kidney disease. Although rare, topical sodium sulfacetamide may cause local irritation.

For additional important information about Kerol(TM) Topical Suspension or ROSULA® Clarifying Wash(TM) please view full prescribing information at www.bradpharm.com or request full prescribing information by contacting Bradley Pharmaceuticals at 973-882-1505.

Please visit Bradley Pharmaceuticals web site at: www.bradpharm.com.

About Bradley Pharmaceuticals, Inc.

Bradley Pharmaceuticals, Inc. was founded in 1985 as a specialty pharmaceutical company and markets to niche physician specialties in the U.S. and international markets. Bradley's success is based upon its core strengths in marketing and sales, which enable the company to Commercialize brands that fill unmet patient and physician needs; Develop new products through life cycle management; and In-License phase II and phase III drugs with long-term intellectual property protection that upon approval leverage Bradley's marketing and sales expertise to increase shareholder value. Bradley Pharmaceuticals is comprised of Doak Dermatologics, specializing in therapies for dermatology and podiatry; Kenwood Therapeutics, providing gastroenterology, OB/GYN, respiratory and other internal medicine brands; and A. Aarons, which markets authorized generic versions of Doak and Kenwood therapies.

Safe Harbor for Forward-Looking Statements:

This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that address activities, events or developments that Bradley expects, believes or anticipates will or may occur in the future, such as Bradley's plans to in-license, develop and launch new and enhanced products with long-term intellectual property protection or other significant barriers to market entry, sales and earnings estimates, other predictions of financial performance, timing of payments on indebtedness, launches by Bradley of new products, market acceptance of Bradley's products, and the achievement of initiatives to enhance corporate governance and long-term shareholder value. Forward-looking statements are based on Bradley's experience and perception of current conditions, trends, expected future developments and other factors it believes are appropriate under the circumstances and are subject to numerous risks and uncertainties, many of which are beyond Bradley's control. These risks and uncertainties include Bradley's ability to: launch VEREGEN(TM) at the end of 2007; predict the safety and efficacy of ELESTRIN(TM) and VEREGEN(TM) in a commercial setting; estimate sales; maintain adequate inventory levels; implement the returns and inventory optimization plan timely, if at all; reduce product returns; comply with the restrictive covenants under its credit facility; refinance its credit facility; access the capital markets on attractive terms or at all; favorably resolve the pending SEC informal inquiry; maintain or increase sales of its products; or effectively react to other risks and uncertainties described from time to time in Bradley's SEC filings, such as fluctuation of quarterly financial results, estimation of product returns, chargebacks, rebates and allowances, concentration of customers, reliance on third party manufacturers and suppliers, litigation or other proceedings (including the pending class action and shareholder derivative lawsuits), government regulation and stock price volatility. Further, Bradley cannot accurately predict the impact on its business of the approval, introduction, or expansion by competitors of generic or therapeutically equivalent or comparable versions of Bradley's products or of any other competing products. In addition, actual results may differ materially from those projected. Bradley undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.


Source: Bradley Pharmaceuticals

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.